On February 13, 2023, the patient underwent FRα expression testing using a folate test kit provided by a third-party testing center through immunohistochemical methods, with results indicating: FRα positive (tumor cell membrane positivity ratio 95%, staining intensity 3 +) (Fig. 2a). Consequently, the patient commenced the fourth-line of treatment with mirvetuximab Soravtansine monoclonal antibody on February 15, 2023, receiving a total of four treatments by April 19, 2023. The gene discussed is FOLR1; the disease is neoplasm.